Suven Life Sciences has successfully converted 3,17,68,764 warrants into equity shares, resulting in a significant capital infusion of Rs 425.7 crore. The shares were allotted to the promoter group entity, Jasti Property and Equity Holdings Private Limited, at an issue price of Rs 134 per share. This transaction increases the company's total paid-up equity capital from 23.19 crore shares to 26.37 crore shares. The receipt of 100% consideration from the promoters demonstrates strong internal confidence in the company's long-term value.

Suven Life Sciences has successfully converted 3,17,68,764 warrants into equity shares, allotting them to the promoter group entity, Jasti Family Trust. The transaction was executed at an issue price of Rs. 134 per share, resulting in a total fund infusion of Rs. 425.70 crore. This capital injection has increased the company's total paid-up equity share capital to 26.37 crore shares. The 100% receipt of consideration from the promoter highlights strong internal support for the company's long-term objectives.

Suven Life Sciences has successfully raised ₹60 crore through the allotment of 44.77 lakh equity shares to 3P India Equity Fund entities. This allotment follows the conversion of fully paid warrants at an issue price of ₹134 per share, which is a significant premium over the face value. Consequently, the company's paid-up equity share capital has increased to 23.19 crore shares. Additionally, the company announced the appointment of Ms. Sangeetha Laxmi Kandari as the new Company Secretary and Compliance Officer, effective February 2, 2026, following the resignation of Mr. Shrenik Soni.

Suven Life Sciences has approved the allotment of 44,77,612 equity shares following the conversion of fully paid warrants, raising approximately ₹60 crore. The shares were issued to 3P India Equity Fund entities at a price of ₹134 per share, increasing the total paid-up capital to 23.19 crore shares. Alongside this capital infusion, the company announced a transition in its secretarial department. Mr. Shrenik Soni has resigned as Company Secretary, and Ms. Sangeetha Laxmi Kandari, who brings over 9 years of experience, will take over the role effective February 2, 2026.

Suven Life Sciences has approved the allotment of 44,77,612 equity shares following the conversion of fully paid warrants. The shares were issued at a price of Rs. 134 per share, resulting in a total capital infusion of approximately Rs. 60 crore from non-promoter entities, specifically 3P India Equity Fund. This conversion increases the company's total paid-up equity share capital to 23.19 crore shares. Additionally, the company announced a change in its Key Managerial Personnel, with a new Company Secretary taking over in February 2026.

Suven Life Sciences has successfully converted 44,77,612 warrants into equity shares, resulting in a capital infusion of approximately Rs 60 crore. The shares were allotted to 3P India Equity Fund entities at an issue price of Rs 134 per share, which includes a premium of Rs 133. This conversion has increased the company's total paid-up equity share capital to 23.19 crore shares. Alongside this fundraise, the company announced a transition in its compliance leadership, appointing Ms. Sangeetha Laxmi Kandari as the new Company Secretary.

Suven Life Sciences has achieved 100% patient enrollment for its Phase-2b clinical trial of Ropanicant, a treatment for Major Depressive Disorder, more than two months ahead of schedule. The trial successfully randomized 195 patients across 35 sites in the USA within just six months of initiation. Management expects the last patient to complete the study by February 2026, with topline efficacy and safety data anticipated in May 2026. This rapid enrollment reflects strong investigator interest and accelerates the timeline for a key clinical asset.